Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma. [electronic resource]
Producer: 20130312Description: 423-30 p. digitalISSN:- 1528-0020
- Aged
- Antineoplastic Agents -- therapeutic use
- Combined Modality Therapy
- Dendritic Cells -- cytology
- Drug Synergism
- Female
- Galactosylceramides -- metabolism
- Humans
- Killer Cells, Natural -- drug effects
- Lenalidomide
- Lymphocyte Activation -- drug effects
- Male
- Middle Aged
- Monocytes -- cytology
- Multiple Myeloma -- drug therapy
- Thalidomide -- analogs & derivatives
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.